Tocilizumab (TCZ)
population PBPK/PD
Recently, the FDA has approved a randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the safety and efficacy of intravenous (IV) tocilizumab (Actemra, TCZ) plus standard of care in hospitalized adult patients with severe coronavirus disease 2019 (COVID-19) pneumonia NCT04320615. Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
The in silico workbench is intended for use by researchers to assist with clinical trial design and for exploratory and educational purposes. It is NOT intended for use in the diagnosis, cure, mitigation or treatment of any disease. Data provided are not intended to suggest that any product and/or dosing regimen are safe and effective for any use and are for informational purposes only. Please see Terms and Conditions for additional information.
